SPOTLIGHT -
The Fine Art (and Science) of Nonprescribing
For many psychiatric conditions, psychotherapy, not medication, is the preferred first-line treatment.
The Rolling Stones Lesson for the Solar Eclipse
Did you view the solar eclipse? What was your experience?
The Role of Psychiatry in Advocating for Diverse Patient Populations in Primary Care Teams
How can consulting psychiatrists help the team provide culturally appropriate care for diverse patient populations?
A Year of Record-High Suicide Rates
The suicide rate in the United States recently reached its highest peak since 1941.
The Many Meanings of Solar Eclipses
Are you watching the solar eclipse?
The Week in Review: April 1-5
From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.
Alcohol Use Disorder Research Roundup: April 5, 2024
What is new in research on alcohol use disorder?
"The Garden of Eden"
"rescued from the filth of paradise, hosed off, shining, my cracked fingernails caked with dirt."
Our Journey Begins: The Total Solar Eclipse and Searching for Personal Sunshine
Will your eyes be on the sky for the total solar eclipse?
National Alcohol Screening Day 2024
In honor of this year’s National Alcohol Screening Day, here’s a look back at some recent coverage in Psychiatric Times about the diagnosis, treatment, and management of alcohol misuse.
MDMA-Assisted Therapy Shows Significant Positive Response on Self-Experience in Patients With PTSD
Lykos Therapeutics recently received priority review of MDMA-assisted therapy for patients with PTSD. Check out the latest research update here!
The Therapeutic Alliance in Psychiatry and Beyond
How does the therapeutic alliance apply outside of psychiatry?
FDA: Specific Fast Track Designation for Subcutaneous Formulation of Leqembi for Alzheimer Disease Needed for Rolling Review
This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.
The Hidden Toll of COVID-19
How has COVID-19 affected your patients of all ages? One psychiatrist weighs in.
Growing Interest in Psychiatry and Religion
Can the growing interest in psychiatry and religion contribute to more healing rather than harm?
First Patient Dosed in Phase 2 Clinical Trial of NBI-1070770 for MDD
“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”
ALTO-203 for Major Depressive Disorder and Anhedonia: Phase 2 Study Initiated
New phase 2 study initiated to determine the potential of ALTO-203 as an antidepressant in patients with major depressive disorder and anhedonia.
“The Web of Meaning”: Family Therapy is Social Psychiatry’s Therapeutic Branch
What are the links between social psychiatry and the family therapy movement?
FDA Approves Fanapt for Mixed, Manic Episodes Associated With Bipolar I Disorder
The atypical antipsychotic was approved for the acute treatment of schizophrenia in 2009.
Have You Seen the Translating Research Into Practice Column?
Have you checked out the latest Translating Research Into Practice column? Let us know!
Simone Veil: A Portrait of a Courageous Leader
An example of a female leader…
Rejoyn Becomes First Prescription Digital Therapeutic Authorized for Treatment of MDD
The FDA has cleared the first prescription digital therapeutic for major depressive disorder, Rejoyn.
First Participant Enrolled in Phase 3 Trial of Fasedienol for Social Anxiety Disorder
Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.
Are Future Predictions Foolish?
Trying to predict the future: foolish or wise?
Presenting Our April Theme: Addiction and SUDs
Write to us now to be part of our series focused on addiction and substance use disorders this month.
From the Pages of Psychiatric Times: March 2024
The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.
The Week in Review: March 25-29
From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.
An Update on Bipolar I Disorder
Our Mood Disorders Section Editor discusses the disorder in honor of World Bipolar Day.
Psychiatry in the News: March 2024
Here are some updates from the world of psychiatry throughout the month of March.
ADHD Medications and Long-Term Cardiovascular Risk
“The heart of the matter.” Researchers investigated the risk of cardiovascular disease associated with long-term ADHD medication use.
